Iron Deficiency Anemia Treatment Guidelines

Initial Oral Iron Therapy

• The American Gastroenterological Association recommends starting with oral iron supplementation at 50-100 mg elemental iron once daily taken on an empty stomach, reserving intravenous iron for patients with intolerance, malabsorption, ongoing blood loss, or inflammatory conditions 1
• Prescribe 50-100 mg elemental iron once daily in the fasting state as the optimal initial regimen, balancing efficacy with tolerability, with ferrous sulfate 200 mg tablets being the simplest and least expensive option 1, 2, 3
• Alternate-day dosing produces similar hemoglobin increments with significantly lower nausea rates, though slower initial response, and lower daily doses produce faster hemoglobin rise but similar ultimate outcomes 1, 2
• Ferric maltol 30 mg twice daily is better tolerated than traditional salts but more expensive and slower to replenish stores, normalizing hemoglobin in 63-66% at 2 weeks and 89% at 1 year 3

Monitoring Response

• Check hemoglobin at 2 weeks: absence of at least 10 g/L rise predicts subsequent treatment failure with 90.1% sensitivity and 79.3% specificity, and recheck hemoglobin every 4 weeks until normalized 1, 2
• Typical response shows hemoglobin improvement within 1 month of oral therapy, and continue oral iron for 2-3 months after hemoglobin normalization to replenish iron stores 1, 2, 4, 5

Intravenous Iron Therapy

• The European Society for Medical Oncology indicates that intravenous iron is reserved for patients with intolerance, malabsorption, ongoing blood loss, or inflammatory conditions, with ferric carboxymaltose and ferric derisomaltose being suitable options 1, 4, 6
• IV iron formulations, such as ferric carboxymaltose, ferric derisomaltose, iron sucrose, and iron dextran, have different dosing regimens, costs, and requirements for test doses 1, 4, 6, 7, 8
• IV iron produces clinically meaningful hemoglobin response within 1 week and is more effective than oral therapy in chronic disease, continuing blood loss, impaired absorption, or GI inflammatory pathology 1, 2, 3

Blood Transfusion

• The American College of Gastroenterology recommends that transfusion is rarely required and should be reserved for severe symptomatic anemia with circulatory compromise, targeting hemoglobin 70-90 g/L, and must follow with iron replacement 1, 3
• Parenteral iron should be considered as an alternative before transfusion, as each unit of blood contains only ~200 mg elemental iron, insufficient to replenish stores in severe IDA 1, 3

Special Populations

• The European Crohn’s and Colitis Organisation states that parenteral iron is more effective than oral therapy in patients with active inflammatory bowel disease, and intolerance and malabsorption of oral iron are particular problems 6, 9
• The American Heart Association indicates that parenteral iron improves symptoms, quality of life, and exercise capacity in patients with chronic heart failure and iron deficiency, even without anemia 9, 10
• The National Kidney Foundation recommends that functional iron deficiency is common in patients with chronic kidney disease, and IV iron formulations are specifically approved for this indication 9, 7, 8

Iron Deficiency Anemia Treatment Guidelines

Special Population Considerations

• The European Crohn's and Colitis Organization recommends using IV iron as first-line therapy for patients with inflammatory bowel disease and hemoglobin <10 g/dL, as it has greater efficacy than oral iron in achieving hemoglobin increase and is better tolerated 11, 12, 13
• IV iron has an odds ratio of 1.57 (95% CI 1.13-2.18) for achieving a hemoglobin increase of 2.0 g/dL and an odds ratio of 0.27 (95% CI 0.13-0.59) for discontinuation rates compared to oral iron in patients with inflammatory bowel disease 11, 12, 13
• Oral iron may be appropriate only in carefully selected patients with mild anemia, clinically inactive disease, and demonstrated tolerance, requiring close follow-up, as recommended by the European Crohn's and Colitis Organization 11, 12, 13
• Treatment must first address underlying inflammation to control ulceration and chronic blood loss in patients with inflammatory bowel disease, as recommended by the European Crohn's and Colitis Organization 11, 12, 13
• IV iron is preferred in post-bariatric surgery patients, particularly in severe cases or when oral supplementation is ineffective, with a single dose being more effective and better tolerated than oral ferrous fumarate or ferrous gluconate in women after Roux-en-Y gastric bypass 11, 12
• Esophagogastroduodenoscopy should be performed to exclude anastomotic ulcer disease causing chronic bleeding in post-bariatric surgery patients 11, 12
• Oral iron therapy is sufficient for patients with portal hypertensive gastropathy, as there is no known malabsorptive defect, though IV iron is reasonable in those with severe iron depletion, and underlying cirrhosis and portal hypertension should be addressed with nonselective β-blockers, transjugular intrahepatic portosystemic shunts, or liver transplantation 13

Intravenous Iron Therapy

• IV iron is suitable for patients with malabsorption, such as those with celiac disease or post-bariatric surgery, as recommended by the Clinical Gastroenterology and Hepatology society 11

Treatment of Iron Deficiency Anemia with Elevated CRP

Understanding the Clinical Context

• When CRP is elevated (>4 mg/L), ferritin levels up to 100 μg/L may still indicate true iron deficiency, because ferritin is an acute phase reactant, according to the European Crohn’s and Colitis Organisation 14, 15

Treatment Algorithm

• The European Society of Clinical Nutrition recommends using IV iron as initial therapy when CRP is elevated, particularly if hemoglobin <10 g/dL, or clinical evidence of active inflammatory disease 14, 16
• The European Society of Gastroenterology recommends continuing iron therapy for 2-3 months after hemoglobin normalization to replenish stores 16

Critical Monitoring

• The American Gastroenterological Association recommends monitoring CRP alongside hemoglobin to assess whether inflammation is resolving, and rechecking hemoglobin every 4 weeks until normalized 14, 15

Underlying Disease Management

• The European Crohn’s and Colitis Organisation recommends treating the inflammatory condition, such as IBD, chronic infection, autoimmune disease, or malignancy, concurrently with iron therapy, as iron therapy alone will not succeed if active inflammation persists 14

Common Pitfalls to Avoid

• The British Society of Gastroenterology recommends not delaying iron replacement while awaiting investigations, unless colonoscopy is imminent, and not interpreting ferritin 30-100 μg/L as "adequate" when CRP is elevated 14, 15, 16, 17